Please login to the form below

Not currently logged in
Email:
Password:

veliparib

This page shows the latest veliparib news and features for those working in and with pharma, biotech and healthcare.

GSK’s Zejula challenges AZ/Merck’s Lynparza in PARP inhibitor category

GSK’s Zejula challenges AZ/Merck’s Lynparza in PARP inhibitor category

Also looking to carve a piece of the PARP inhibitor market in ovarian cancer is AbbVie, who also revealed positive data in this therapy area with its candidate veliparib.

Latest news

More from news
Approximately 1 fully matching, plus 12 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

InSite Events™ National Pharma Meeting: A Customer Story
How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
Fear or encouragement, which is best to drive behaviour change?
The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
The unheard, unseen, and uncorrected effects of COVID-19
The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...

Infographics